Medical device manufacturers and digital health developers face a complex operational environment as artificial intelligence and software become embedded in more medical technologies. In this landscape, companies must balance the pressure to innovate quickly with the responsibility to protect patients. Navigating this dynamic requires early legal involvement to help manufacturers avoid costly setbacks and better operationalize compliance.
According to Suzanne Levy Friedman, Partner at Honigman, regulatory counsel helps organizations determine whether products fall under FDA oversight, distinguish wellness technologies from regulated devices, and build effective commercialization strategies. The regulatory framework maintained by the FDA serves as a critical guardrail, ensuring that innovations entering the market meet safety benchmarks.
The intersection of rapid innovation, particularly in AI, and the FDA’s responsibility to protect public health creates ongoing tension. Bridging this gap requires manufacturers to build compliance into their operational workflows from the earliest stages of product conceptualization.
Distinguishing Wellness Tech from Regulated Devices
One of the primary challenges for digital health startups and established medtech firms alike is establishing the exact classification of their products. Regulatory counsel helps organizations distinguish wellness technologies from regulated devices.
Working with specialized regulatory counsel helps organizations map their product features against statutory definitions. By clarifying regulatory status early, developers can design software architecture that satisfies requirements before submitting formal applications for market clearance or approval.
Managing the AI Innovation Cycle and Public Health Protection
Artificial intelligence introduces regulatory questions. There is a growing tension between rapid innovation, particularly in AI, and the FDA’s responsibility to protect public health.
Operationalizing compliance in this environment demands transparent documentation, rigorous testing, and proactive communication with regulators.
Industry stakeholders can explore ongoing developments, connect with legal professionals, and review regulatory updates by visiting the Honigman website or reaching out to Suzanne Levy Friedman directly via email at [email protected], as well as following Honigman on LinkedIn and connecting with Suzanne Levy Friedman on LinkedIn for professional insights into digital health law.
Next Steps for Medtech Compliance
As regulatory agencies continue to refine guidance for artificial intelligence and digital health tools, medical technology companies must monitor policy updates and engage with legal experts early in the product lifecycle. Early regulatory planning can help medtech companies innovate responsibly, reduce risk, and bring valuable technologies to patients more efficiently.
Worth a look